Edwards Lifesciences Q3 FY25: where the revenue came from and where it went
The whole income statement of Edwards Lifesciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 5, 2025
Revenue$1.55B
+15% year over year
Gross profit$1.21B
78% margin
Operating profit$0.31B
20% margin
Net profit$0.29B
19% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.55 | 100% | +15% |
| Aortic valve replacement | 1.15 | 74% | +12% |
| Surgical heart valve therapy | 0.26 | 17% | +8% |
| Transcatheter mitral | 0.15 | 9% | +59% |
| Cost of revenue | −0.35 | 22% | |
| Gross profit | 1.21 | 78% margin | −3pp |
| R&D | −0.28 | 18% | −1pp |
| SG&A | −0.51 | 33% | +2pp |
| Other | −0.11 | 7% | |
| Operating profit | 0.31 | 20% margin | −6pp |
| Other income, net | 0.04 | ||
| Tax | −0.06 | ||
| Net profit | 0.29 | 19% margin | −208pp |
154 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest